WO2002013758A3 - Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle - Google Patents

Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle Download PDF

Info

Publication number
WO2002013758A3
WO2002013758A3 PCT/FR2001/002606 FR0102606W WO0213758A3 WO 2002013758 A3 WO2002013758 A3 WO 2002013758A3 FR 0102606 W FR0102606 W FR 0102606W WO 0213758 A3 WO0213758 A3 WO 0213758A3
Authority
WO
WIPO (PCT)
Prior art keywords
transcript
interest
transgene
expression
inhibitor
Prior art date
Application number
PCT/FR2001/002606
Other languages
English (en)
Other versions
WO2002013758A2 (fr
Inventor
Daniel Scherman
Michael Bettan
Pascal Bigey
Original Assignee
Aventis Pharma Sa
Daniel Scherman
Michael Bettan
Pascal Bigey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0010730A external-priority patent/FR2813085A1/fr
Application filed by Aventis Pharma Sa, Daniel Scherman, Michael Bettan, Pascal Bigey filed Critical Aventis Pharma Sa
Priority to AU2001285990A priority Critical patent/AU2001285990A1/en
Priority to IL15450801A priority patent/IL154508A0/xx
Priority to EP01965323A priority patent/EP1311298A2/fr
Priority to CA002419790A priority patent/CA2419790A1/fr
Priority to JP2002518906A priority patent/JP2004505647A/ja
Publication of WO2002013758A2 publication Critical patent/WO2002013758A2/fr
Publication of WO2002013758A3 publication Critical patent/WO2002013758A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

La présente invention concerne de nouvelles constructions, compositions et un nouveau procédé pour la régulation de l'expression d'un transgène d'intérêt in vivo par inhibition conditionnelle, ainsi que leurs utilisations dans les domaines expérimentaux, cliniques, thérapeutiques, ou pour la production d'animaux ou végétaux. Plus particulièrement, le nouveau procédé de régulation repose sur la coexpression d'un transgène d'intérêt codant pour un transcrit d'intérêt et d'un transgène inhibiteur codant pour un transcrit inhibiteur spécifique du transcrit d'intérêt, de sorte à obtenir une inhibition constitutive de l'activité du transcrit d'intérêt, et à pouvoir assurer une régulation efficace du transcrit d'intérêt, soit par inhibition de son transcrit inhibiteur, soit par activation du transcrit d'intérêt, soit encore par activation du transcrit d'intérêt et inhibition concomitante de son transcrit inhibiteur.
PCT/FR2001/002606 2000-08-18 2001-08-10 Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle WO2002013758A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001285990A AU2001285990A1 (en) 2000-08-18 2001-08-10 System for regulating in vivo the expression of a transgene by conditional inhibition
IL15450801A IL154508A0 (en) 2000-08-18 2001-08-10 System for regulating in vivo the expression of a transgene by conditional inhibition
EP01965323A EP1311298A2 (fr) 2000-08-18 2001-08-10 Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle
CA002419790A CA2419790A1 (fr) 2000-08-18 2001-08-10 Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle
JP2002518906A JP2004505647A (ja) 2000-08-18 2001-08-10 条件的阻害によるトランスジーンの発現をインビボで調節する方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0010730A FR2813085A1 (fr) 2000-08-18 2000-08-18 Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle
FR00/10730 2000-08-18
US23924600P 2000-10-11 2000-10-11
US60/239,246 2000-10-11

Publications (2)

Publication Number Publication Date
WO2002013758A2 WO2002013758A2 (fr) 2002-02-21
WO2002013758A3 true WO2002013758A3 (fr) 2002-07-18

Family

ID=26212583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/002606 WO2002013758A2 (fr) 2000-08-18 2001-08-10 Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle

Country Status (7)

Country Link
US (2) US20020166132A1 (fr)
EP (1) EP1311298A2 (fr)
JP (1) JP2004505647A (fr)
AU (1) AU2001285990A1 (fr)
CA (1) CA2419790A1 (fr)
IL (1) IL154508A0 (fr)
WO (1) WO2002013758A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447453A1 (fr) * 2003-02-13 2004-08-18 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Sysème pour rendre un gène silencieux de manière inductible, locale et reversible, en utilisant l'interférence d'un ARN
CA2545697C (fr) * 2003-11-14 2016-12-20 Richard Mulligan Ribozymes a autoclivage et leurs utilisations
EP1799825B1 (fr) 2004-10-05 2011-06-29 The California Institute of Technology Acides nucleiques a regulation d'aptameres et leurs utilisations
US20060200878A1 (en) 2004-12-21 2006-09-07 Linda Lutfiyya Recombinant DNA constructs and methods for controlling gene expression
EP3372676A1 (fr) * 2004-12-21 2018-09-12 Monsanto Technology, LLC Constructions d'adn recombinant et procédés pour réguler l'expression génique
EP2985353A1 (fr) 2006-10-12 2016-02-17 Monsanto Technology LLC Micro-arn de plantes et leurs procédés d'utilisation
WO2008058291A2 (fr) 2006-11-09 2008-05-15 California Institute Of Technology Ribosymes modulaires régulés par les aptamères
WO2009011855A2 (fr) * 2007-07-16 2009-01-22 California Institute Of Technology Sélection de domaines de capteur à base d'acide nucléique dans une plate-forme d'échange d'acide nucléique
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8865667B2 (en) 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
JP6385644B2 (ja) * 2013-03-13 2018-09-05 静岡県公立大学法人 目的遺伝子を発現させるための光学スイッチ用コンストラクト
EP3455358B1 (fr) * 2016-05-12 2020-08-26 Janssen Vaccines & Prevention B.V. Promoteur bidirectionnel puissant et équilibré
CN110650624A (zh) * 2017-03-10 2020-01-03 威斯康星州医药大学股份有限公司 用于视网膜疾病的核糖开关调节的基因治疗

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008830A1 (fr) * 1989-01-26 1990-08-09 Imperial Chemical Industries Plc Production de semences hybrides
WO1996000587A1 (fr) * 1994-06-30 1996-01-11 University Of Pittsburgh Capsides de virus adeno-associe utilises comme vecteurs pour le transfert moleculaire
WO1997044465A1 (fr) * 1996-05-20 1997-11-27 Monsanto Company Procede de regulation de la germination de graines au moyen de sequences d'acyl-coa oxydase du soja
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US6048850A (en) * 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
WO2001036616A2 (fr) * 1999-11-18 2001-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008830A1 (fr) * 1989-01-26 1990-08-09 Imperial Chemical Industries Plc Production de semences hybrides
US6048850A (en) * 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
WO1996000587A1 (fr) * 1994-06-30 1996-01-11 University Of Pittsburgh Capsides de virus adeno-associe utilises comme vecteurs pour le transfert moleculaire
WO1997044465A1 (fr) * 1996-05-20 1997-11-27 Monsanto Company Procede de regulation de la germination de graines au moyen de sequences d'acyl-coa oxydase du soja
WO2001036616A2 (fr) * 1999-11-18 2001-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOSSEN M ET AL: "TRANSCRIPTIONAL ACTIVATION BY TETRACYCLINES IN MAMMALIAN CELLS", SCIENCE, vol. 268, 23 June 1995 (1995-06-23), pages 1766 - 1769, XP000606285, ISSN: 0036-8075 *
JEN KUANG-YU ET AL: "Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies", STEM CELLS, vol. 18, no. 5, September 2000 (2000-09-01), pages 307 - 319, XP002181426, ISSN: 1066-5099 *
OHKAWA J. ET AL.: "Control of the functional activity of an antisense RNA by a tetracyclin-responsive derivative of the human U6 snRNA promoter", HUMAN GENE THERAPY, vol. 11, no. 4, 1 March 2000 (2000-03-01), pages 577 - 585, XP000926522 *

Also Published As

Publication number Publication date
AU2001285990A1 (en) 2002-02-25
JP2004505647A (ja) 2004-02-26
CA2419790A1 (fr) 2002-02-21
US20050289658A1 (en) 2005-12-29
IL154508A0 (en) 2003-09-17
WO2002013758A2 (fr) 2002-02-21
EP1311298A2 (fr) 2003-05-21
US20020166132A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
WO2002013758A3 (fr) Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle
WO2004002417A3 (fr) Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
WO2005081687A3 (fr) Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes
WO2005032460A3 (fr) Mimeticorps de noyau charniere mimetiques de l'epo humaine, compositions, procedes et applications correspondantes
WO2003084477A3 (fr) Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
WO2005097175A3 (fr) Corps mimetiques glp-1 humains, compositions, procedes et utilisations
PL371582A1 (en) Difluoromethyl thiazolyl carboxanilides
WO2008011446A3 (fr) Mimétiques de la glp-1 humaine, compositions, procédés et utilisations
WO2003022228A3 (fr) Procede de production d'oiseaux et de poissons transgeniques
WO2003078639A3 (fr) Enzymes d'expression de plantes transgeniques impliquees dans la biosynthese d'acides gras
CA2056396A1 (fr) Extraction de la phytase vegetale
WO2002090493A3 (fr) Genes de delta 4-desaturase et leurs applications
PL363303A1 (en) Composition for regulating animal growth, method of manufacture and use thereof
WO2000031283A3 (fr) Sequences regulatrices utiles pour l'expression genetique dans des tissus embryonnaires vegetaux
AU2003247824A1 (en) Genetic manipulation of condensed tannins
WO2007076319A3 (fr) Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations
AU2002210310A1 (en) Method of selecting plant promoters to control transgene expression
MXPA03002079A (es) Plantas resistentes enfermedades y metodo para obtener las mismas.
WO2004016749A3 (fr) Modulation antisens de l'expression de l'acyl-coa synthetase 1
NZ596626A (en) Synthesis of sialic acid in plants
AU2003245086A1 (en) Novel polypeptide having function of 7-keto-8-aminopelargonic acid synthase of plant and method for inducing growth inhibition and lethality by suppressing expression of the polypeptide
WO2002066666A3 (fr) Procede pour la production d'acide d-pantothenique ou de ses sels comme additif a des aliments pour animaux
WO2003082206A3 (fr) Proteines derivees de l'immunoglobuline liees a la sclerose en plaques, compositions, methodes et utilisations relatives
AU2001282194A1 (en) Biological control method against mosses, algae, fungi and other micro-organismsas well as the method to improve the growth of the plants
WO2007081302A3 (fr) Miméticorps de la glp-1 humaine, compositions, procédés et utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001285990

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 154508

Country of ref document: IL

Ref document number: 2001965323

Country of ref document: EP

Ref document number: 2002518906

Country of ref document: JP

Ref document number: 2419790

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 524474

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2001965323

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001965323

Country of ref document: EP